The COPD drug combination known as Breo in the US and Relvar in Europe (fluticasone and vilanterol) has given mixed results but is seen as positive for Theravance, whose share price has surged.
Drug pricing in the US is a perennial topic, which is no surprise given the the US spends more per capita on prescription medicines than any other country. This is not just down to the volume of ...
AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback